---
title: "Dupixent (dupilumab) in atopic dermatitis: Pharmacology questions"
description: "Pharmacology questions on Dupixent (dupilumab) in atopic dermatitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: Is Dupixent an immunosuppressant? How is Dupixent metabolized? How long does Dupixent stay in your system? What are the inactive ingredients in Dupixent? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Dupixent (dupilumab) in atopic dermatitis: Pharmacology questions

Manufacturer: sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.  
Prescribing information: [Dupixent](https://www.regeneron.com/downloads/dupixent_fpi.pdf)

## Mechanism

<a id="dupixent-immunosuppressant"></a>

### Is Dupixent an immunosuppressant?

> “DUPIXENT is not an immunosuppressant and avoids broad immunosuppression<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Mechanism of Action for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action#:~:text=DUPIXENT%20is%20not%20an%20immunosuppressant%20and%20avoids%20broad)

> “It is unknown if DUPIXENT will influence the immune response against helminth infections<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Mechanism of Action for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action#:~:text=It%20is%20unknown%20if%20DUPIXENT%20will%20influence%20the%20immune%20response%20against%20helminth)

> “Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and 
> interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 
> and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and 
> both IL-4 and IL-13 signaling through the Type II receptor.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 31, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=31)

Note: This is the manufacturer's statement; the Prescribing Information does not classify DUPIXENT as an immunosuppressant.

<a id="dupixent-mechanism"></a>

### How does Dupixent work in atopic dermatitis (mechanism of action)?

> “DUPIXENT binds to IL-4 receptor alpha, inhibiting IL-4 and IL-13 induced inflammatory responses<sup>1,2</sup>
> The mechanism of dupilumab action has not been definitively established.”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Mechanism of Action for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action#:~:text=DUPIXENT%20binds%20to%20IL%2D4%20receptor,has%20not%20been%20definitively%20established.)

> “Dupilumab is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and 
> interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 
> and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor and 
> both IL-4 and IL-13 signaling through the Type II receptor.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 31, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=31)

## Pharmacokinetics

<a id="dupixent-metabolism"></a>

### How is Dupixent metabolized?

> “DUPIXENT is not metabolized through the liver or excreted through the kidneys<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Mechanism of Action for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action#:~:text=DUPIXENT%20is%20not%20metabolized%20through%20the%20liver%20or%20excreted%20through%20the)

> “The metabolic pathway of dupilumab has not been characterized. As a human monoclonal IgG4 
> antibody, dupilumab is expected to be degraded into small peptides and amino acids via 
> catabolic pathways in the same manner as endogenous IgG.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 33, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=33)

Note: The first passage is the manufacturer's website statement; the Prescribing Information states that the metabolic pathway of dupilumab has not been characterized and that it is expected to be degraded in the same manner as endogenous IgG.

<a id="dupixent-time-in-body"></a>

### How long does Dupixent stay in your system?

> “After the last steady-state dose of 
> 300 mg QW, 300 mg Q2W, 200 mg Q2W, 300 mg Q4W, or 200 mg Q4W dupilumab, the 
> median times to non-detectable concentration (<78 ng/mL) ranged from 9 to 13 weeks in adults 
> and pediatric subjects 12 years of age and older. Population pharmacokinetic analyses indicate 
> the median times to non-detectable concentration are approximately 1.5 times (up to 19 weeks) 
> and 2.5 times (up to 32 weeks) longer in pediatric subjects 6 to 11 years of age and pediatric 
> subjects 6 months to 5 years of age, respectively.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 33, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=33)

Note: The Prescribing Information states times to non-detectable concentration and does not state a half-life.

## Components

<a id="dupixent-inactive-ingredients"></a>

### What are the inactive ingredients in Dupixent?

> “Inactive ingredients: L-arginine hydrochloride, L-histidine, polysorbate 80, sodium acetate, sucrose, and water for injection.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 80, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=80)

> “Each 300 mg pre-filled syringe or pre-filled pen delivers 300 mg dupilumab in 2 mL which also 
> contains L-arginine hydrochloride (10.5 mg), L-histidine (6.2 mg), polysorbate 80 (4 mg), 
> sodium acetate (2 mg), sucrose (100 mg), and water for injection, pH 5.9. 
> Each 200 mg pre-filled syringe or pre-filled pen delivers 200 mg dupilumab in 1.14 mL which 
> also contains L-arginine hydrochloride (12 mg), L-histidine (3.5 mg), polysorbate 80 (2.3 mg), 
> sodium acetate (1.2 mg), sucrose (57 mg), and water for injection, pH 5.9.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 31, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=31)

## Related pages
- [Medical information: Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis)
- [Indication](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/guidelines)
